CLINICAL TRIALS PROFILE FOR DARIFENACIN
✉ Email this page to a colleague
All Clinical Trials for DARIFENACIN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00127270 ↗ | Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder | Completed | Procter and Gamble | Phase 4 | 2005-05-01 | This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies. |
NCT00127270 ↗ | Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder | Completed | Novartis | Phase 4 | 2005-05-01 | This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies. |
NCT00170755 ↗ | A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder | Completed | Novartis | Phase 3 | 2002-04-01 | This study will evaluate the safety, tolerability and efficacy of darifenacin, in the long-term treatment of adult patients with overactive bladder. |
NCT00170768 ↗ | Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over | Completed | Novartis | Phase 2 | 2005-02-01 | The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin. |
NCT00171145 ↗ | A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. | Completed | Novartis | Phase 3 | 2004-04-01 | This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB. |
NCT00171184 ↗ | Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder | Completed | Procter and Gamble | Phase 4 | 2005-04-01 | The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks treatment with darifenacin in patients aged >Ý 65 years with OAB. |
NCT00171184 ↗ | Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder | Completed | Novartis | Phase 4 | 2005-04-01 | The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks treatment with darifenacin in patients aged >Ý 65 years with OAB. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DARIFENACIN
Condition Name
Clinical Trial Locations for DARIFENACIN
Trials by Country
Clinical Trial Progress for DARIFENACIN
Clinical Trial Phase
Clinical Trial Sponsors for DARIFENACIN
Sponsor Name